Riskpilot← Back to searchSign inGet full accessSwedland Pharma AB
ABActiveOrg 5592560063Gjutjärnsgatan 2 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 20202 employees
Revenue 2025
SEK 9,1M
-1% vs 2024
EBITDA margin
1.5%
+397% vs 2024
Equity ratio
48.6%
Financial strength
Net profit 2025
SEK 310K
+21577% vs 2024
| Revenue | SEK 9,1M | -1% |
| EBITDA | SEK 136K | +397% |
| Net profit | SEK 310K | +21577% |
| Total assets | SEK 3,1M | +10% |
| Equity | SEK 1,5M | +26% |
| Employees | 2 | — |
Legal name
Swedland Pharma AB
Org number
5592560063
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 maj 2020
Share capital
SEK 200 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva försäljning av apoteks, receptbelagda, receptfria mediciner, hälsokost samt vård och omsorgsverksamhet därmed förenlig verksamhet. Företaget kommer att jobba med affärsutveckling för att importera och exportera samt distribution av medicinsk och kliniska produkter och dylikt. Företaget kommer att arbeta med medicinska utrustningar, läkemedel, tandvård, skönhet och sjukvårdsprodukter. Företaget kommer dessutom arbeta med konsultverksamhet för rådgivning och marknadsföring.
Address
Gjutjärnsgatan 2 A
Email
swedland.pharma@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 258 | 10 527 | 9 347 | 9 225 | 9 102 |
| Staff expenses | — | −1 029 | −796 | −1 237 | −898 |
| EBITDA | 489 | 725 | 394 | −46 | 136 |
| Depreciation & amort. | −37 | −20 | −20 | −20 | −13 |
| EBIT | 452 | 704 | 374 | −66 | 123 |
| Net financials | — | −5 | −3 | −8 | 1 |
| Profit before tax | 371 | 526 | 277 | 6 | 392 |
| Tax | −50 | −108 | −59 | −4 | −82 |
| Net profit | 321 | 417 | 219 | 1 | 310 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 231 | 3 275 | 3 209 | 2 789 | 3 062 |
| Equity | 539 | 957 | 1 175 | 1 177 | 1 487 |
| Long-term debt | 0 | — | — | — | 750 |
| Short-term debt | 1 612 | 2 065 | 1 686 | 1 345 | 825 |
| Total debt | 1 612 | 2 065 | 1 686 | 1 345 | 1 575 |
EBITDA margin
1.5%
This company
15.8%
Market median
-91% vs market
20212025
Equity ratio
48.6%
This company
38.2%
Market median
+27% vs market
20212025
Return on equity
20.9%
This company
18.4%
Market median
+14% vs market
20212025
Net profit margin
3.4%
This company
8.1%
Market median
-58% vs market
20212025
Asset turnover
2.97×
This company
1.12×
Market median
+165% vs market
20212025
Debt / equity
1.06×
This company
0.62×
Market median
-71% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (3) | ||
| Board of Directors | 2026 – 2026 | |
| Deputy Board Member | 2026 – 2026 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Swedland Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rania Fadel Shaban Elsharafi | Deputy Board Member | 0 companies |
| Mohamad Tarchhani | Board of Directors | 0 companies |
| Amel Jaffar Mahmoud | Board of Directors | 0 companies |
| Walid Kheder Antouan Katan | Deputy Board Member | 0 companies |
| Nada Samara | Deputy Board Member | 0 companies |